VREX Therapeutics

VREX Therapeutics was a private U.S. biotechnology company focused on developing oncolytic immunotherapies for solid tumors. The company was founded in 2020 around the work of Feng Yao from Harvard Medical School and Brigham and Women's Hospital, and it centered its approach on the SOVI platform, an engineered oncolytic herpes simplex virus system designed to control viral replication and transcription of immunomodulatory payloads in the tumor microenvironment. Its lead disclosed program, SOVI-001, was described as an engineered fusogenic HSV-1 oncolytic virus with large payload capacity. Publicly available sources indicate the company remained at a preclinical stage and did not disclose clinical trial advancement. Third-party company databases later described VREX Therapeutics as deadpooled, suggesting it is no longer operating as an active venture-backed biotech.